Chugai Pharmaceutical Co., Ltd. [Head Office: Chuo-ku, Tokyo; President: Osamu Nagayama (hereafter, &20;Chugai̶] introduced today it has joined into license contracts with F. Hoffmann-La Roche, Ltd [Head Office: Basel, Switzerland / CEO: Severin Schwan (hereafter, “Ro”)] covng humanized anti-Met antibody MetMAb, for non-small cell cancer of the lung (NSCLC) and humanized anti-interleukin(IL)-13 antibody lebrikizumab for bronchial bronchial asthma that are both presently produced by Roche with the Personalized Health care (PHC) approach and also have also joined phase I studies within the Japanese population. (Source: Roche Investor Update) More details: Informations...
Tags: Health, Initiates, F. Hoffmann-, clinical …
